NYSE:ABC - AmerisourceBergen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $169.82
  • Forecasted Upside: 21.44 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.87 (-0.62%)

This chart shows the closing price for ABC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AmerisourceBergen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABC

Analyst Price Target is $169.82
▲ +21.44% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for AmerisourceBergen in the last 3 months. The average price target is $169.82, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 21.44% upside from the last price of $139.84.

This chart shows the closing price for ABC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in AmerisourceBergen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/13/2022UBS GroupBoost Price TargetBuy$144.00 ➝ $174.00High
6/9/2022CowenLower Price TargetOutperform$171.00 ➝ $170.00Medium
6/9/2022CowenLower Price Target$171.00 ➝ $170.00Medium
6/7/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$167.00 ➝ $178.00Low
6/3/2022Evercore ISILower Price Target$165.00Low
5/27/2022Morgan StanleyLower Price TargetEqual Weight$178.00 ➝ $175.00Medium
5/26/2022BarclaysUpgradeEqual Weight ➝ Overweight$175.00 ➝ $182.00Low
5/25/2022Deutsche Bank AktiengesellschaftLower Price Target$168.00 ➝ $167.00Low
5/5/2022Robert W. BairdBoost Price Target$179.00 ➝ $187.00Low
5/5/2022Deutsche Bank AktiengesellschaftBoost Price Target$153.00 ➝ $168.00Low
5/5/2022MizuhoBoost Price Target$139.00 ➝ $162.00Low
4/12/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$142.00 ➝ $178.00Low
3/14/2022ArgusBoost Price Target$140.00 ➝ $160.00Medium
2/3/2022Robert W. BairdBoost Price Target$175.00 ➝ $179.00Medium
2/3/2022MizuhoBoost Price TargetNeutral$130.00 ➝ $139.00Low
1/11/2022BarclaysBoost Price TargetEqual Weight$135.00 ➝ $152.00High
1/6/2022ScotiabankDowngradeOutperform ➝ Sector PerformHigh
12/17/2021Morgan StanleyBoost Price TargetOverweight$141.00 ➝ $142.00Medium
11/12/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$136.00 ➝ $153.00High
11/8/2021Credit Suisse GroupBoost Price TargetOutperform$144.00 ➝ $145.00Medium
11/5/2021BarclaysBoost Price TargetEqual Weight$130.00 ➝ $135.00Low
8/31/2021Morgan StanleyBoost Price TargetOverweight$138.00 ➝ $141.00Medium
8/5/2021Credit Suisse GroupBoost Price TargetOutperform$132.00 ➝ $144.00High
8/5/2021Robert W. BairdBoost Price TargetOutperform$156.00 ➝ $162.00High
6/20/2021Robert W. BairdReiterated RatingBuyMedium
5/6/2021BarclaysBoost Price TargetEqual Weight$122.00 ➝ $130.00Low
2/9/2021MizuhoBoost Price TargetNeutral$104.00 ➝ $114.00Low
2/8/2021Morgan StanleyBoost Price TargetOverweight$130.00 ➝ $138.00Medium
2/8/2021CowenBoost Price TargetOutperform$145.00 ➝ $150.00Low
2/5/2021Credit Suisse GroupBoost Price TargetOutperform$123.00 ➝ $127.00Low
2/4/2021Evercore ISIUpgradeIn-Line ➝ OutperformLow
2/1/2021CowenBoost Price TargetOutperform$129.00 ➝ $145.00Low
1/21/2021ArgusBoost Price TargetBuy$120.00 ➝ $140.00Medium
1/7/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$111.00 ➝ $115.00N/A
1/6/2021Bank of AmericaUpgradeUnderperform ➝ NeutralN/A
11/13/2020MizuhoBoost Price TargetNeutral$100.00 ➝ $104.00Medium
11/9/2020Credit Suisse GroupBoost Price TargetOutperform$118.00 ➝ $123.00Low
11/9/2020Morgan StanleyBoost Price TargetOverweight$121.00 ➝ $130.00Low
11/6/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$104.00 ➝ $111.00Low
8/10/2020UBS GroupBoost Price TargetBuy$99.00 ➝ $112.00Low
8/10/2020Credit Suisse GroupBoost Price TargetOutperform$111.00 ➝ $118.00Low
8/6/2020Morgan StanleyBoost Price TargetOverweight$112.00 ➝ $121.00High
7/21/2020Bank of AmericaBoost Price TargetUnderperform$85.00 ➝ $88.00Medium
6/15/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$94.00 ➝ $112.00Medium
5/15/2020UBS GroupLower Price TargetBuy$108.00 ➝ $99.00High
5/11/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$93.00 ➝ $98.00Medium
5/8/2020Morgan StanleyBoost Price TargetEqual Weight$84.00 ➝ $94.00High
4/22/2020Credit Suisse GroupInitiated CoverageBuy$105.00Low
4/1/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$93.00 ➝ $106.00Medium
3/27/2020Morgan StanleyLower Price TargetEqual Weight$98.00 ➝ $84.00Medium
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$112.00Medium
2/2/2020Credit Suisse GroupReiterated RatingBuy$98.00Low
1/31/2020Robert W. BairdBoost Price TargetNeutral$93.00 ➝ $94.00High
1/31/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$79.00 ➝ $93.00High
1/19/2020BarclaysReiterated RatingHold$100.00Low
11/18/2019ArgusReiterated RatingBuy$110.00Low
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$91.00High
9/6/2019Morgan StanleyLower Price TargetEqual Weight$91.00 ➝ $83.00N/A
6/3/2019ArgusLower Price TargetBuy$115.00 ➝ $100.00Medium
4/11/2019GuggenheimInitiated CoverageBuyLow
4/10/2019Bank of AmericaDowngradeBuy ➝ Underperform$95.00 ➝ $76.00High
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformHigh
1/17/2019UBS GroupInitiated CoverageBuy ➝ Buy$89.00Medium
1/6/2019BarclaysReiterated RatingHold$84.00Low
12/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$88.00 ➝ $91.00Low
11/30/2018Royal Bank of CanadaLower Price TargetSector Perform ➝ Hold$90.00 ➝ $87.00Low
11/7/2018Royal Bank of CanadaSet Price TargetHold$90.00Low
9/19/2018MizuhoReiterated RatingNeutralMedium
8/12/2018MizuhoReiterated RatingHold$90.00Low
8/3/2018Robert W. BairdReiterated RatingHold$89.00Medium
7/20/2018Robert W. BairdDowngradeOutperform ➝ NeutralLow
7/20/2018Robert W. BairdReiterated RatingOutperform ➝ Neutral$94.00Low
7/3/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$97.00 ➝ $88.00Low
4/2/2018Royal Bank of CanadaSet Price TargetHold$101.00Medium
3/27/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$104.00 ➝ $95.00Low
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$104.00Low
3/5/2018ArgusBoost Price TargetBuy$93.96 ➝ $115.00Low
2/27/2018CowenReiterated RatingBuy$108.00Low
2/27/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$111.00High
2/8/2018Needham & Company LLCLower Price TargetBuy ➝ Buy$117.00 ➝ $113.00Medium
2/7/2018Jefferies Financial GroupSet Price TargetHold$95.00Medium
2/7/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$105.00 ➝ $112.00Medium
2/7/2018Royal Bank of CanadaReiterated RatingHold$102.00Medium
1/24/2018MizuhoSet Price TargetHold$100.00Low
1/23/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$88.00 ➝ $108.00Low
1/4/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$105.00Medium
1/2/2018SVB LeerinkSet Price TargetBuy$90.00 ➝ $105.00Low
12/15/2017The Goldman Sachs GroupUpgradeNeutral ➝ BuyHigh
12/12/2017CowenSet Price TargetBuy$107.00Low
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$97.00High
12/1/2017Robert W. BairdSet Price TargetBuy$99.00High
11/22/2017Needham & Company LLCBoost Price TargetBuy$86.00 ➝ $88.00N/A
11/6/2017Robert W. BairdReiterated RatingBuy$96.00N/A
11/6/2017Needham & Company LLCLower Price TargetBuy$93.00 ➝ $86.00N/A
10/29/2017Jefferies Financial GroupSet Price TargetHold$85.00N/A
10/24/2017MizuhoSet Price TargetHold$92.00N/A
10/24/2017Needham & Company LLCSet Price TargetBuy$93.00N/A
10/10/2017CowenUpgradeMarket Perform ➝ OutperformN/A
10/5/2017Robert W. BairdUpgradeNeutral ➝ Outperform$89.00 ➝ $96.00N/A
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$87.00Medium
9/14/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
9/10/2017Needham & Company LLCReiterated RatingBuy$91.00Medium
8/29/2017Jefferies Financial GroupSet Price TargetHold$95.00Low
8/7/2017SVB LeerinkSet Price TargetOutperform ➝ Buy$100.00 ➝ $90.00Low
8/4/2017UBS GroupLower Price TargetNeutral ➝ Neutral$94.00 ➝ $87.00Low
7/13/2017Credit Suisse GroupReiterated RatingOutperform ➝ Buy$95.00Low
(Data available from 7/7/2017 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 28 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 30 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 7 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 4 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 37 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 2 very positive mentions
  • 25 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 25 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
AmerisourceBergen logo
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $139.84
Low: $139.54
High: $141.73

50 Day Range

MA: $149.17
Low: $139.84
High: $161.30

52 Week Range

Now: $139.84
Low: $111.34
High: $167.19


1,525,029 shs

Average Volume

1,286,761 shs

Market Capitalization

$29.29 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of AmerisourceBergen?

The following equities research analysts have issued reports on AmerisourceBergen in the last year: Argus, Barclays PLC, Cowen Inc, Cowen Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, Mizuho, Morgan Stanley, Robert W. Baird, Scotiabank, StockNews.com, TheStreet, and UBS Group AG.
View the latest analyst ratings for ABC.

What is the current price target for AmerisourceBergen?

0 Wall Street analysts have set twelve-month price targets for AmerisourceBergen in the last year. Their average twelve-month price target is $169.82, suggesting a possible upside of 21.4%.
View the latest price targets for ABC.

What is the current consensus analyst rating for AmerisourceBergen?

AmerisourceBergen currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABC will outperform the market and that investors should add to their positions of AmerisourceBergen.
View the latest ratings for ABC.

What other companies compete with AmerisourceBergen?

How do I contact AmerisourceBergen's investor relations team?

AmerisourceBergen's physical mailing address is 1300 MORRIS DRIVE, CHESTERBROOK PA, 19087. The company's listed phone number is (610) 727-7000 and its investor relations email address is [email protected] The official website for AmerisourceBergen is www.amerisourcebergen.com. Learn More about contacing AmerisourceBergen investor relations.